Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients

Xun, Zhen; Liu, Can; Yu, Qingqing; Lin, Jinpiao; Huang, Jinlan; Yang, Ting-Wen; Wu, Weihong; Wu, Songhang; Ou, Qishui

doi:10.1016/j.cca.2019.12.020

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Xun et al . reported that ALBI score was correlated with the effectiveness of pegylated interferon and nucleos(t)ide analogues in patients with CHB [17]. However, the sample size was relatively small and the follow-up time was short.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Baseline albumin-bilirubin score: a predictor for HBeAg clearance in patients with chronic hepatitis B after nucleos(t)ide analogue treatment

Zhang,

Gu,

Yin

et al. 2023

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Background Serum biomarkers for predicting HBeAg clearance in patients with chronic hepatitis B (CHB) virus infection during antiviral therapy remain lacking. This study aimed to investigate baseline albumin-bilirubin (ALBI) score for assessing HBeAg clearance in HBeAg-positive CHB patients treated with nucleos(t)ide analogues (NAs). Methods Six hundred and ninety-nine HBeAg-positive CHB patients treated with first-line NAs were retrospectively included. Kaplan–Meier curves were used to compare the possibility of HBeAg clearance and HBeAg seroconversion in different ALBI groups. Cox regression models were used to identify factors associated with HBeAg clearance and HBeAg seroconversion. Results Of the patients, 69.8% were male, with a median age of 36.0 years. 174 (24.9%) patients achieved HBeAg clearance after a median of 92.0 (interquartile range 48.0–134.0) weeks of antiviral treatment and 108 (15.5%) patients achieved HBeAg seroconversion. 74.0% and 26.0% of patients were classified as ALBI grade 1 and ALBI grade 2-3, respectively. ALBI grade 2-3 was identified as an independent predictor of HBeAg clearance (hazard ratio 1.570, 95% confidence interval 1.071–2.301, P = 0.021). The cumulative incidence of HBeAg clearance and HBeAg seroconversion was significantly higher in ALBI grade 2-3 group than group of ALBI grade 1 (P < 0.001). Similar results were observed in different subgroups with different antiviral drugs, cirrhosis status, and ALT levels. Conclusion Baseline ALBI score may be a valuable indicator for predicting antiviral response in HBeAg-positive CHB patients treated with NAs.

show abstract

Section: Discussionmentioning

confidence: 99%

“…There were still limited data about the value of ALBI in predicting the therapeutic efficacy of CHB patients. Xun et al reported that ALBI score was correlated with the effectiveness of pegylated interferon and nucleos(t) ide analogues in patients with CHB [17]. However, the sample size was relatively small and the follow-up time was short.…”

Section: Discussionmentioning

confidence: 99%